Full face rejuvenation
Fernando Felice outlines his individual approach to full face rejuvenation, including the use of CO2 resurfacing as well as hyaluronic acid and botulinum toxin injections. An attractive face respects facial...
Read MoreAuthor: Pluto Luong Van
What’s the best way to match the implant to the breast? Evidence on implant size selection systems reviewed
How should plastic surgeons choose the best implant type and size for women undergoing breast augmentation surgery? Implant size selection systems based on breast tissue measurements may provide better outcomes,...
Read Moreevolis® Introduces Science-Backed FGF5-Inhibiting Hair Care Line for Hair Loss Reversal and Prevention
A new hair loss prevention and reversal line launching in December 2016 is poised to disrupt the $3.5 billion hair loss market in the US where over 80 million people...
Read MoreResearch on rare genetic disease reveals new stem cell pathway
In a study published in the journal Proceedings of the National Academy of Sciences, Shinya Yamanaka, MD, PhD, who first created induced pluripotent stem cells (iPSCs), and his colleagues at...
Read MoreNew study suggests way to slow skin fibrosis in scleroderma
The prognosis for patients diagnosed with scleroderma – an autoimmune disease characterized by fibrosis of the skin – is not typically a rosy one. With limited treatment options available, those...
Read MoreElectronic records help identify two genes linked to age-related hearing impairment
A study of electronic records and genome sequences from adults with age-related hearing impairment identified two genetic variations linked to the disorder, report Thomas Hoffmann of the University of California, San Francisco...
Read MoreCU researchers identify genes related to vitiligo
For the past decade, Richard Spritz’s lab at the University of Colorado Anschutz Medical Campus has been searching for potential causes of vitiligo, an autoimmune disease that gives rise to...
Read MorePhase 3 results for Sun Pharma’s investigational psoriasis medicine, tildrakizumab
Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in patients with...
Read More
March/April 2024 Issue
